Navigation Links
New gene therapy strategy boosts levels of deficient protein in Friedreich's ataxia
Date:7/25/2012

New Rochelle, NY, July 25, 2012A novel approach to gene therapy that instructs a person's own cells to produce more of a natural disease-fighting protein could offer a solution to treating many genetic disorders. The method was used to achieve a 2- to 3-fold increase in production of a protein deficient in patients with Friedreich's ataxia, as described in an article published Instant Online in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com) The article is available free online at the Human Gene Therapy website (http://www.liebertpub.com/hum).

The innovative gene therapy method described by Jacques Tremblay, Pierre Chapdelaine, Zo Coulombe, and Joel Rousseau, Laval University, Quebec, and University of Quebec, Canada, takes advantage of the ability of a family of proteins called Tal effector (TALE) proteins to target specific DNA sequences. As a model of how this method could be used to treat genetic disease, the authors engineered TALE proteins to target the gene that codes for the frataxin protein, which is deficient in Friedreich's ataxia. The ability to induce cells to produce more frataxin could reduce symptoms of the disease and provide an effective, long-term therapeutic strategy, conclude the authors in the article "TALE Proteins Induce the Expression of the Frataxin Gene. (http://online.liebertpub.com/doi/full/10.1089/hum.2012.034)

"This is a very clever approach to treat a recessive disease caused by decreased quantity of an otherwise normal protein," says James M. Wilson, MD, PhD, Editor-in-Chief, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.


'/>"/>
Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100 x2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology technology :

1. Gene Therapy - Technologies, Markets and Companies
2. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
3. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
4. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
5. Squamous Cell Cancer Responds to SPDT Therapy
6. Stem cell therapy reverses diabetes
7. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
8. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
9. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 New gene therapy strategy boosts levels of deficient protein in Friedreich's ataxia
(Date:3/29/2017)... 29, 2017 Patients are the most compelling ... Behring awards Local Empowerment for Advocacy Development (LEAD) grants ... These groups tackle complex legislative and public policy issues ... and in statehouses across the U.S. ... awarded to New England Hemophilia Association (NEHA), Neuropathy Action ...
(Date:3/29/2017)... - Last year,s petition to the White House signed by ... to generate awareness on the importance of new organic medicines and ... market place. ... Earlier this month Health Advance (OTC PINK: HADV ... products, announced its endeavors on this generally recognized as safe ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ComplianceOnline, the ... subjects has announced its 3rd Annual Medical Device Summit 2017 venue and speaker lineup. ... Parker House Hotel, in Boston, MA. , The Omni Parker House Hotel, which is ...
(Date:3/29/2017)... CA (PRWEB) , ... March 29, 2017 , ... ... cutting edge instrumentation for cell-based assays, disperses a quarterly travel award to noteworthy ... Today the company announced that its new round of awards are being ...
Breaking Biology Technology:
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
Breaking Biology News(10 mins):